CN112656914A - Application of composition in preparation of product for inhibiting prostate cancer - Google Patents
Application of composition in preparation of product for inhibiting prostate cancer Download PDFInfo
- Publication number
- CN112656914A CN112656914A CN202011595650.7A CN202011595650A CN112656914A CN 112656914 A CN112656914 A CN 112656914A CN 202011595650 A CN202011595650 A CN 202011595650A CN 112656914 A CN112656914 A CN 112656914A
- Authority
- CN
- China
- Prior art keywords
- prostate cancer
- composition
- product
- parts
- lycopene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses application of a composition in preparing a product for inhibiting prostate cancer, wherein the composition consists of lycopene and turmeric. In addition, the invention provides a product containing the composition, which has high safety, is suitable for long-term use and has no toxic or side effect; the product has no bad taste, and the raw materials have no bitter and astringent tastes, so that the taste of the product is not influenced when the product is used alone or added into the product, and the product is not difficult to swallow like traditional Chinese medicines.
Description
Technical Field
The invention relates to the technical field of medical products, in particular to application of a composition in preparing a product for inhibiting prostate cancer.
Background
Prostate cancer (Prostate cancer) is the most common malignancy in the male genitourinary system, the second largest malignancy currently second only to skin cancer. The incidence and mortality of prostate cancer tends to increase year by year throughout asia, including china. Sedentary lifestyles, environmental carcinogens, family history of prostate cancer, endogenous factors, and oxidative stress associated with the aging process are all predisposed to inducing prostate cancer. Prostate cancer has become a global health problem as its morbidity, disease burden and mortality have increased.
Disclosure of Invention
Based on the above, the present invention aims to overcome the defects of the prior art and provide the application of a composition in the preparation of a product for inhibiting prostate cancer.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows: use of a composition comprising lycopene and turmeric in the manufacture of a product for inhibiting prostate cancer.
According to the invention, the turmeric and the lycopene are compounded, and the test data show that the raw materials have a synergistic interaction effect for the first time, so that the prostate cancer can be effectively inhibited, and the effect is better than that of single use. The invention provides application of the compound composition in preparation of a product for inhibiting prostate cancer for the first time.
In addition, the composition provided by the invention has high safety and no toxic or side effect, and the turmeric is a medicine and food dual-purpose raw material abroad, is particularly widely applied to india and is a main raw material of curry powder. Turmeric is a food additive and a health food raw material in China, and is widely used in foods. Lycopene is a health food raw material and a food pigment, and the Sunjing test of the public health institute of Nanjing medical university proves that the lycopene is safe and non-toxic. It can be seen that the composition has high safety.
Meanwhile, the two components in the composition can be prepared and extracted according to actual conditions, can be directly purchased from the market, and can be replaced by raw materials, semi-finished products or added finished products with the same components without influencing the efficacy of the prepared product: the Curcuma rhizome can be prepared from Curcuma rhizome; lycopene can be a lycopene-rich material extracted from plants or can be biologically fermented or chemically synthesized to contain lycopene or structural analogs.
Preferably, the composition consists of the following components in parts by weight: 12.5-50 parts of lycopene and 12.5-50 parts of turmeric.
Curcuma rhizome is dried rhizome extract of Curcuma rhizome (Curcuma longa L.) belonging to Curcuma of Zingiberaceae, and has curcumin as main chemical component. Curcuma rhizome has anti-tumor, antioxidant, liver protecting, blood sugar lowering, antiinflammatory, antibacterial, and antiviral effects. Lycopene is one of carotenoid, and has effects of resisting oxidation, scavenging free radicals, protecting cardiovascular and cerebrovascular, and enhancing immunity. The inventor of the application researches the optimal proportion of the compound composition of the turmeric and the lycopene in the preparation of products for inhibiting the prostate cancer through a large number of creative experimental researches. The turmeric and lycopene can improve prostate cancer from multiple sites and multiple ways, and can achieve synergistic effect, thereby improving prostate health.
Preferably, the article further comprises adjuvants including flavoring agents, thickening agents, disintegrating agents, and fillers. On the premise of not influencing the main components of the prostate cancer inhibition product, the necessary auxiliary materials are added in the product to further enhance and provide the taste, the storage stability, the effect and the like of the product, and the person skilled in the art can select the common content according to the conventional standard. More preferably, the article of manufacture comprises a food, pharmaceutical or nutraceutical product.
In addition, the invention provides a preparation method of the product for inhibiting the prostate cancer, which comprises the following steps: and uniformly mixing the composition and the auxiliary materials to obtain the product.
Preferably, the dosage form of the prostate cancer inhibition product comprises solid beverage, granules, capsules and tablets. The preparation form of the product can be adjusted according to the actual requirement on the premise of not influencing the component structure and the component stability of the composition.
Compared with the prior art, the invention has the beneficial effects that:
(1) the product has good effect, the effect of the invention is better than that of the invention which singly uses the turmeric and the lycopene to treat the prostatic cancer, the turmeric and the lycopene are compounded, and the experimental data shows that the raw materials can generate the synergistic interaction effect, and the prostatic cancer can be effectively inhibited.
(2) The food additive is high in safety and suitable for long-term use, all the used raw materials are food additives, the food additive can be applied to common food, and the food additive has no toxic or side effect and is suitable for long-term use.
(3) Has no bad taste, no bitter and astringent taste of the raw materials, no influence on the taste of the product when used alone or added into food, and no difficulty in swallowing like traditional Chinese medicines.
Detailed Description
To better illustrate the objects, aspects and advantages of the present invention, the following examples further illustrate the invention.
Example 1
According to one embodiment of the invention, the composition for inhibiting prostate cancer comprises the following components in parts by weight: 50 parts of lycopene and 12.5 parts of turmeric.
The preparation method of the composition for inhibiting prostate cancer described in the examples is: mixing lycopene and Curcuma rhizome uniformly to obtain the composition.
Example 2
According to one embodiment of the invention, the composition for inhibiting prostate cancer comprises the following components in parts by weight: lycopene 25 parts and turmeric 12.5 parts
The preparation method of the composition for inhibiting prostate cancer described in the examples is: mixing lycopene and Curcuma rhizome uniformly to obtain the composition.
Example 3
According to one embodiment of the invention, the composition for inhibiting prostate cancer comprises the following components in parts by weight: 12.5 parts of lycopene and 12.5 parts of turmeric.
The preparation method of the composition for inhibiting prostate cancer described in the examples is: mixing lycopene and Curcuma rhizome uniformly to obtain the composition.
Example 4
According to one embodiment of the invention, the composition for inhibiting prostate cancer comprises the following components in parts by weight: 12.5 parts of lycopene and 25 parts of turmeric.
The preparation method of the composition for inhibiting prostate cancer described in the examples is: mixing lycopene and Curcuma rhizome uniformly to obtain the composition.
Example 5
According to one embodiment of the invention, the composition for inhibiting prostate cancer comprises the following components in parts by weight: 12.5 parts of lycopene and 50 parts of turmeric.
The preparation method of the composition for inhibiting prostate cancer described in the examples is: mixing lycopene and Curcuma rhizome uniformly to obtain the composition.
Example 6
According to one embodiment of the invention, the composition for inhibiting prostate cancer comprises the following components in parts by weight: 25 parts of lycopene and 12.5 parts of turmeric. The composition is used for preparing a product for inhibiting prostate cancer, and the product also comprises auxiliary materials, wherein the auxiliary materials comprise the following components in parts by weight: 30 parts of flavoring agent, 50 parts of microcrystalline cellulose, 40 parts of maltodextrin, 305 parts of povidone K, 2 parts of silicon dioxide and 3 parts of magnesium stearate.
The preparation method of the prostate cancer inhibiting preparation comprises the following steps: sieving and weighing the raw materials respectively according to the parts by weight, feeding the raw materials into a mixer, uniformly mixing, granulating, tabletting and bottling to prepare tablets, thus obtaining the product.
Example 7
According to one embodiment of the invention, the composition for inhibiting prostate cancer comprises the following components in parts by weight: 12.5 parts of lycopene and 25 parts of turmeric. The composition is used for preparing a product for inhibiting prostate cancer, and the product also comprises auxiliary materials, wherein the auxiliary materials comprise the following components in parts by weight: 4 parts of beeswax, 100 parts of gelatin, 50 parts of glycerol and 100 parts of purified water.
The preparation method of the prostate cancer inhibiting preparation comprises the following steps: mixing, homogenizing, melting gelatin, pressing, washing, drying, selecting pill, and packaging to obtain soft capsule.
Meanwhile, the present application provides comparative examples, specifically the following, which are prepared in the same manner as in example 1:
the prostate cancer-inhibiting composition described in comparative example 1 was only 50 parts of lycopene; the prostate cancer-inhibiting composition described in comparative example 2 was only 25 parts of lycopene; the prostate cancer inhibiting composition of comparative example 3 is only 12.5 parts of lycopene; the prostate cancer-suppressing composition of comparative example 4 is turmeric only 12.5 parts; the prostate cancer-suppressing composition of comparative example 5 is turmeric 25 parts only; the prostate cancer-suppressing composition described in comparative example 6 is only 50 parts of turmeric.
Test examples
First, main material and equipment
1.1. Prostate cancer LNCaP cells;
1.2. dimethyl sulfoxide (DM SO), trypan blue, 1640 culture solution, fetal calf serum and trypsin
1.3. Positive control for effect on prostate cancer LNCaP cells: docetaxel, sample component raw materials: turmeric is provided by Ar juna Natural Extracts Ltd, curcumin content about 50%, lycopene is provided by basf samples, lycopene content about 10%.
1.4.35mm petri dish, carbon dioxide incubator, Cytospin centrifuge, microscope (Nikon Optiphot).
Second, test method
2.1 test groups are shown in Table 1:
TABLE 1 test groups
2.2 test methods
Effect on prostate cancer LNCaP cells
Prostate cancer cells were seeded at a concentration of 0.2X 105The cells/mL were plated in 35mm diameter dishes at 5% CO2 and incubated overnight at 37 ℃. Groups of test samples dissolved in DMSO were added and 72 hours later, the effect of different concentrations of each sample on cell growth and death was determined using trypan blue staining. The specific method comprises the following steps: adherent growing cells were digested with pancreatin, 80 μ L of the cell suspension was uniformly mixed with 20 μ L of 0.4% trypan blue, and after standing for 2 minutes, observed and counted using a microscope (Nikon Optiphot), and under the visual field, clear cells were counted as live cells and trypan blue cells were counted as dead cells.
The percentage of viable cells is the number of component viable cells ÷ the number of blank viable cells × 100%
The inhibition ratio = (number of living cells of blank control-number of component living cells)/number of living cells of blank control x 100% 2.3 test result, and the effect on prostate cancer LNCaP cells is shown in table 2:
TABLE 2 Effect of groups on prostate cancer LNCaP cells
Notes 1.# are relative to the blank control group, relative to the lycopene group at the same concentration, and relative to the turmeric group at the same concentration; 2. three identical symbols indicate p <0.001, two identical symbols indicate p <0.01, and are extremely significant, and one identical symbol indicates p <0.05, and significantly, the smaller the p value, the more significant the difference.
As can be seen from table 2, the positive control group had a significant difference from the blank group, and the test group and the turmeric groups 2 and 3 had a significant difference from the blank group, which indicates that these groups had significant inhibitory effects on prostate cancer LNCaP cells. But the lycopene group and the turmeric group 1 have no significant difference compared with the blank group. The lycopene group and the turmeric group 1 have no obvious inhibition effect on prostate cancer LNCaP cells under the concentration of the experiment.
The test formula 3 has significant difference with respect to the blank group, but the lycopene group and the turmeric group have no significant difference with respect to the blank group under the same concentration. The test groups 1, 2, 4 and 5 have very significant differences in the viable cell rates compared with the lycopene and turmeric groups at the same concentration. Therefore, the turmeric and the lycopene have synergistic effect on the apoptosis of the prostate cancer LNCaP.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (5)
1. Use of a composition comprising lycopene and turmeric in the manufacture of a product for inhibiting prostate cancer.
2. The use according to claim 1, wherein the composition consists of the following components in parts by weight: 12.5-50 parts of lycopene and 12.5-50 parts of turmeric.
3. The use of claim 1 or 2, wherein the article further comprises adjuvants including flavoring agents, thickening agents, disintegrating agents, and bulking agents.
4. The use of claim 3, wherein the article is prepared by a method comprising: and uniformly mixing the composition and the auxiliary materials to obtain the product.
5. The use of claim 4, wherein the prostate cancer inhibitor is in the form of solid beverage, granule, capsule, or tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011595650.7A CN112656914A (en) | 2020-12-28 | 2020-12-28 | Application of composition in preparation of product for inhibiting prostate cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011595650.7A CN112656914A (en) | 2020-12-28 | 2020-12-28 | Application of composition in preparation of product for inhibiting prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112656914A true CN112656914A (en) | 2021-04-16 |
Family
ID=75411961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011595650.7A Withdrawn CN112656914A (en) | 2020-12-28 | 2020-12-28 | Application of composition in preparation of product for inhibiting prostate cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112656914A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108451979A (en) * | 2018-06-28 | 2018-08-28 | 新疆金骏阳光生物科技有限公司 | A kind of lycopene compound preparation and its application with auxiliary treatment prostate cancer |
-
2020
- 2020-12-28 CN CN202011595650.7A patent/CN112656914A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108451979A (en) * | 2018-06-28 | 2018-08-28 | 新疆金骏阳光生物科技有限公司 | A kind of lycopene compound preparation and its application with auxiliary treatment prostate cancer |
Non-Patent Citations (1)
| Title |
|---|
| 爆炸营养课堂: "男人要小心前列腺疾病！医生：排尿困难折磨人，吃2种食物来缓解", 《豆丁网》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101514918B1 (en) | Pears-Belloflower syrup prepared using a mixture of belloflower and pear and the Preparation Method of the Same | |
| KR101949887B1 (en) | Composition for relieving hangover or preventing or treating alcoholic liver disease comprising a complex extract of seaweed and complex extract of plant | |
| Liang et al. | Study on stability and antioxidant activity of red anthocyanidin glucoside rich hybrid rice, its nutritional and physicochemical characteristics | |
| KR101831981B1 (en) | Composition for preventing, improving or treating cancer comprising Sageretia thea extract or its fraction as effective component | |
| EP2792666B1 (en) | Phorbol type diterpene compound, pharmaceutical composition for treatment or prevention of viral infectious diseases including same | |
| CN107996913A (en) | A kind of juice functional additive and preparation method and application | |
| CN112656914A (en) | Application of composition in preparation of product for inhibiting prostate cancer | |
| KR20150014014A (en) | Fermented mulberry composition with antioxidant activity and method of preparing the same | |
| CN112674340A (en) | Application of composition in preparation of product for inhibiting prostate cancer | |
| CN112790381A (en) | Application of composition in preparation of product for inhibiting prostate cancer | |
| KR20160114841A (en) | Composition for improvement or treatment of Fat comprising Eucommiae ulmoides Oliv. Bark. extract or Adiponectin isolated therefrom as active ingredient | |
| KR20150130170A (en) | Pharmaceutical composition for antiinflammatory and preventing or treating immune disease comprising extract of black rice bran | |
| KR20140120756A (en) | Anti-inflammatory pharmaceutical composition comprising tangerine pericarp and Psidium guajava extract | |
| CN112807403A (en) | Application of composition in preparation of product for inhibiting prostate cancer | |
| CN112603982A (en) | Composition for inhibiting prostatic hyperplasia | |
| KR101665875B1 (en) | Composition for treating prostate disease comprising korean native plants | |
| KR101791830B1 (en) | The compositions of anticancer effect of women cancers comprising wheat germ extract and preparation method thereof | |
| TR202008787A2 (en) | USE OF PROPOLICIN OBTAINED BY SPECIAL EXTRACTION METHOD IN LIQUID MIXTURES | |
| CN113577220A (en) | Medicinal composition for inhibiting prostate cancer and application thereof | |
| CN112656915A (en) | Composition for inhibiting prostatic hyperplasia | |
| CN115154506B (en) | Composition for improving anoxic stress state, and preparation method and application thereof | |
| KR20150106187A (en) | Composition for antioxidation comprising the seed extract of cornus officinalis | |
| JP4656277B2 (en) | Apoptosis-inducing substances, potato ingredients and processed products contained in potato anthocyanins | |
| KR101446962B1 (en) | New variety of blackberry, 'Amor' and Composition containing extract of the same | |
| RU2812611C1 (en) | Compositions of ginsenoside rg3 and ginsenoside rg5 and their pharmaceutical uses, including antitumor effects |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210416 |
|
| WW01 | Invention patent application withdrawn after publication |